Ra Capital Management, L.P. Cure Vac N.V. Transaction History

Ra Capital Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.94 - $4.34 $2.29 Million - $3.38 Million	-778,563 Reduced 28.37%	1,965,707 $5.96 Million
Q4 2023 Feb 14, 2024	BUY	$3.96 - $6.41 $10.9 Million - $17.6 Million	2,744,270 New	2,744,270 $11.6 Million
Q3 2023 Nov 14, 2023	SELL	$6.5 - $10.77 $10.7 Million - $17.7 Million	-1,641,611 Reduced 13.41%	10,604,344 $72.4 Million
Q1 2023 May 15, 2023	BUY	$6.38 - $12.5 $78.1 Million - $153 Million	12,245,955 New	12,245,955 $85.4 Million

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $538M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Ra Capital Management, L.P. with notifications on news.